MEETING REPORT
PMA Liaison Report on the 1991 Drug Safety Subsection Meeting The Pharmaceutical Manufacturers Association (PMA) Drug Metabolism Subsection and Drug Safety Subsection (DRUSAFE) 1991 Joint Annual Meeting was held in New Orleans, LA, from October [13] [14] [15] [16] 1991 . This report is a brief account of selected excerpts from the meeting.
Dr. R. Michael McClain (Director of Toxicology at Hoffmann-LaRoche Inc.) presented an extensive update of PMA activities and issues that included the following: 1) The 1992 DRUSAFE Meeting will be held in October in Tempe, AZ; the 1993 Meeting will be held in Austin, TX, at Barton Creek; 2) DRUSAFE has formed a committee to provide feedback on new regulatory guidelines; 3) PMA has formed a task force to discuss the Sprague-Dawley 2-yr study survival problem; current Food and Drug Administration (FDA) status is that they will not reject a study if a &dquo;simple survival problem occurs.&dquo; The obvious long-term solution is to breed a better rat; 4) FDA recommends protocol/dose approval prior to the start of a carcinogenicity study, and they will respond within 2 weeks. Participants emphasized that this was still nonbinding; 5) PMA prefers to do only rat carcinogenicity studies. This idea has only slight support in the FDA and other regulatory agencies; 6) PMA supports the idea of moving away from maximum tolerated dose (MTD) towards maximum acceptable dose (MAD), which is based more on toxicokinetic data; 7) PMA prefers that carcinogen-study drug exposure be described as &dquo;total drug delivered vs fraction of the lifespan.&dquo; This is preferred over simple plasma or tissue drug levels because tumors arise in tissues where carcinogens have caused an accumulation of irreversible changes; 8) PMA prefers 6-month studies instead of 1-yr chronic studies because the 1-yr study adds little, it any, new information over a 6-month study. FDA will probably continue to require 1-yr studies; 9) Dr. G. Reid Patterson ( proposal for all biologics. Dr. Cavagnaro said that preclinical studies should be done to provide relevant scientific information to the regulators to allow them to do an appropriate safety assessment. Preclinical studies should not be done to fulfill regulatory requirements. She said the worst thing to be seen in preclinical studies was no toxicity because the reason for preclinical studies was to detect potential adverse reactions.
Dr. Peter G. Welling (Vice President Pharmacokinetics at Parke-Davis/Wamer Lambert) presented a talk entitled, &dquo;The Practical Use of Kinetics in Toxicity Testing.&dquo; First, let us review a few definitions. &dquo;Kinetics&dquo; is the activity of the body on the drug (absorptions, distribution, metabolism, and excretion). &dquo;Dynamics&dquo; is the activity of the drug on the body (altered physiological function). In pharmacokinetics, the drug is administered at pharmacologic doses; this is a well-established field. In toxicokinetics, the drug is administered at toxicologic doses; this is a new emerging field.
Dr. Welling emphasized that it is no longer sufficient to conduct a toxicology study on a dose-response basis. Pharmacokinetics does not equal toxicokinetics for the following reasons: 1) Stability is often concentration-dependent; 2) First pass clearance, protein binding, and renal excretion are all saturable processes; 3) Metabolism rate and pathway may change as dose increases; 4) All of the above can alter bioavailability; and 5) Physiologic feedback and receptor activity/affinity can change at toxic doses. mg/kg given to rats at 2 pm caused 90% mortality, whereas when dosed at 10 pm, it caused no mortality. Diurnal variation may be important in cancer chemotherapy. Pulse labeling studies of liver mitoses showed 10-fold more mitoses at 10 am versus midnight. They also observed that as a rat gets older, the amount of food eaten during the dark decreases, whereas the amount eaten during light increases. Measurement of corticosterone is one way to detail circadian rhythms.
Dr. Joyce Mordenti (Group Leader/Manager, Pharmacokinetics at Genentech Inc.) presented a talk entitled, &dquo;Scaling in Interspecies Assessment.&dquo; Scaling across species is important because organ size proportionately increases as body size decreases (the liver in the mouse is a greater percentage of the body weight than in the dog), and blood circulation is much faster in the mouse than in the dog (mouse has faster clearance). Scaling can aid in projecting dose equivalents and, thus, help set doses in Phase III clinical trials.
Dr. Judy Weissinger (Assistant Director, Office of New Drug Evaluation at the FDA) presented a talk entitled, &dquo;Use of Pharmacodynamics and Pharmacokinetics in Non-Clinical Studies, Pharmacology-Toxicology Studies.&dquo; She emphasized that the use of kinetic, dynamic, and metabolic profiles is very important for the following reasons/purposes: 1) planning of toxicology studies (selection of species, dose, and routes); 2) determination of the need for specialized studies (e.g., enzyme induction); 3) predictability of observed pharmacologic and toxicologic ranges to help define the mechanism of toxicity and the relevance of human risk; 4) characterization of drug interactions and aging changes; 5) characterization of the risk due to pathophysiology (renal and/or hepatic impairment, and hypertension); 6) evaluation of stereoisomeric relationships ; 7) evaluation of changes in drug formulations and/or impurity profile; and 8) extrapolation of animal data to man.
Dr. Weissinger said that at the FDA there is one person who receives the pharmacology, metabolism, toxicology, and pathology data in a new drug application (NDA). It is very hard for the FDA reviewer to piece together information from these 4 different parts of the NDA. It would be very useful for the NDA issuer to provide an integrated summary of these 4 areas.
In conclusion, the general message from many of the speakers was that toxicokinetic/toxicodynamic data are going to become increasingly important in the future. Currently, many studies are conducted without the use of toxicokinetic data to select doses.
It is obvious that toxicokinetics will play an increasingly important role in dose selection in toxicology and/or carcinogenicity studies; however, that role is certain to be the basis for abundant future debate. DARRELL L. TUOMARI, D.V.M., Ph.D.
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